Építés alatt – nem éles oldal
Belépés
Leállítva1/2. fázis

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

A legfontosabb adatok

Ki végzi
Pfizer
Hol
Albuquerque, Cincinnati, Columbia, Columbus, Detroit, Fort Lauderdale, Gilbert, Grosse Pointe Woods, Honolulu, Iowa City, Lenexa, Meridian, Mesa, Miami, New York, Norfolk, Omaha, Palo Alto, Reno, Rochester, San Antonio, Silver Spring, Somers Point, Tomball, Walnut Creek, Washington D.C. és Wilmington (Egyesült Államok)Mind a 35 helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
1/2. fázis
Résztvevők
484 fő vett részt
Kezdés
2023. jan. 25.
Befejezés
2025. szept. 23.
A vizsgálat típusa
Beavatkozással járó, 14 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
  • Candidate 1: PF-07915234: VZV modRNA Suspension for Injection
  • Candidate 2: PF-07921188: VZV modRNA Suspension for Injection
  • Candidate 3: PF-07921186: VZV modRNA Suspension for Injection
  • Shingrix
  • Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
A regiszteradat frissítve
2026. május 4.
Miért állt le
Strategic decision made by the company

Ki vehet részt

Életkor
50 év – 85 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 47 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female participants 50 through 69 years of age (inclusive) at the time of consent
  • Healthy participants who are determined by clinical assessment, including medical history and clinical judgment of the investigator, to be eligible for inclusion in the study. Note: Known infection with HIV, HCV or HBV is an exclusion in Substudy A
  • Participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol; Substudy A: Group 11 to Group 14
  • Male or female participants 50 through 69 years of age (inclusive) at the time of consent
  • Healthy participants who are determined by clinical assessment, including medical history and clinical judgment of the investigator, to be eligible for inclusion in the study. Note: Known infection with HIV, HCV or HBV is an exclusion in Substudy A
  • Participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol
  • Has a body mass index (BMI) between 18 and 35 (inclusive) kg/m2 at the screening visit; Substudy A: Group 1 to Group 10
  • Male or female participants 50 through 85 years of age (inclusive) at the time of consent
  • Healthy participants who are determined by clinical assessment, including medical history and clinical judgment of the investigator, to be eligible for inclusion in the study
  • Participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol
  • Has a BMI between 18 and 35 (inclusive) kg/m2 at the screening visit

Ki nem vehet részt

  • Prior history of heart disease (eg, heart failure, recent coronary artery disease, cardiomyopathies, pericarditis/myocarditis)
  • Previous vaccination with any varicella or HZ vaccine
  • Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study
  • Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study
  • Any participant who has received or plans to receive an RNA vaccine 28 days prior to Vaccination 1
  • Participation in other interventional studies within 28 days prior to study entry or anticipated involvement through and including 6 months after the last dose of study intervention. Participation in observational studies is permitted
  • Participation or planned participation in strenuous or endurance exercise within 7 days before or after each study intervention administration
  • Prior history of heart disease (eg, heart failure, recent coronary artery disease, cardiomyopathies, pericarditis, or myocarditis)
  • Previous vaccination with any varicella or HZ vaccine
  • Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study
  • Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study
  • Any participant who has received or plans to receive an RNA vaccine 28 days prior to Vaccination 1
  • Participation in other interventional studies within 28 days prior to study entry or anticipated involvement through and including 6 months after the last dose of study intervention is prohibited. Participation in observational studies is permitted
  • History of HZ (shingles)
  • History of Guillain-Barré syndrome
  • Known infection with HIV, HCV, or HBV
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s)
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
  • History of HZ (shingles)
  • History of Guillain-Barré syndrome
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s)
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
  • Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
  • Any screening hematology and/or blood chemistry laboratory value that meets the definition of a ≥ Grade 1 abnormality; or any abnormal bilirubin or troponin I value
  • Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
  • Women who are pregnant or breastfeeding
  • Screening 12-lead ECG that, as judged by the investigator, is consistent with probable or possible myocarditis/pericarditis or demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members; SubStudy B:
  • Women who are pregnant or breastfeeding
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members

Egyéb feltételek

  • Substudy A: Group 1 to Group 10

Helyszínek itt: Egyesült Államok

  • IMA Clinical ResearchAlbuquerque, Egyesült Államok
  • CTI Clinical Research CenterCincinnati, Egyesült Államok
  • Centennial Medical GroupColumbia, Egyesült Államok
  • Centricity Research Columbus Ohio MultispecialtyColumbus, Egyesült Államok
  • Columbus Cardiovascular Associates, Inc.Columbus, Egyesült Államok
  • C.S. Mott Clinical Research Center (CRC)Detroit, Egyesült Államok
  • Proactive Clinical Research,LLCFort Lauderdale, Egyesült Államok
  • Tri-City CardiologyGilbert, Egyesült Államok
  • Henry Ford St. John HospitalGrosse Pointe Woods, Egyesült Államok
  • East-West Medical Research InstituteHonolulu, Egyesült Államok
  • University of IowaIowa City, Egyesült Államok
  • Johnson County Clinical TrialsLenexa, Egyesült Államok
  • Solaris Clinical ResearchMeridian, Egyesült Államok
  • West Valley Cardiology ServicesMeridian, Egyesült Államok
  • Aventiv Research, IncMesa, Egyesült Államok
  • Acevedo Clinical Research AssociatesMiami, Egyesült Államok
  • Icahn School of Medicine at Mount SinaiNew York, Egyesült Államok
  • NYU Langone HealthNew York, Egyesült Államok
  • Tisch HospitalNew York, Egyesült Államok
  • Velocity Clinical Research - NorfolkNorfolk, Egyesült Államok
  • Quality Clinical ResearchOmaha, Egyesült Államok
  • Stanford University Medical CenterPalo Alto, Egyesült Államok
  • University of Nevada School of Medicine - RenoReno, Egyesült Államok
  • Rochester Clinical Research, LLCRochester, Egyesült Államok
  • Clinical Trials of Texas LLCSan Antonio, Egyesült Államok
  • Clinical Trials of Texas, LLC., dba Flourish ResearchSan Antonio, Egyesült Államok
  • IMA Clinical Research San AntonioSan Antonio, Egyesült Államok
  • Associates in Cardiology PASilver Spring, Egyesült Államok
  • South Jersey Infectious DiseaseSomers Point, Egyesült Államok
  • Dynamed Clinical Research, LP d/b/a DM Clinical ResearchTomball, Egyesült Államok
  • Diablo Clinical Research, Inc.Walnut Creek, Egyesült Államok
  • GW Medical Faculty AssociatesWashington D.C., Egyesült Államok
  • GW Vaccine Research UnitWashington D.C., Egyesült Államok
  • Accellacare - WilmingtonWilmington, Egyesült Államok
  • Wilmington Health, PLLC (Cardiologist)Wilmington, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune system's reaction) of the study vaccine called Varicella Zoster Virus modRNA (VZV modRNA). We are seeking for healthy participants 50 through 85 years of age.

A teljes eredeti leírásKevesebb

This study will be conducted in 2 substudies: Substudy A (Phase 1) and Substudy B (Phase 2).

Substudy A:

This substudy is the Phase 1 portion of the study. In this substudy, participants will receive 1 of 3 VZV modRNA vaccine candidates (different construct, different dose levels and different formulation [frozen or freeze dry powder]) or the approved shingles vaccine intramuscularly.

Participants will be assigned in 1 of 10 groups in the study. Vaccination will be given either as a 2-dose series using one of two dosing schedules (either 2-months apart or 6-months apart), or (in one of the groups), as a single VZV modRNA vaccine at the first vaccination visit and saline at the second vaccination visit.

Participants will take part in this study for 8 to 12 months depending on the group they are assigned to. Some group(s) will continue into persistence-of-immunity (overtime assessment of effect of vaccine) portion of the study. Those participants assigned to these selected groups will be involved in the study for up to 5 years.

Substudy B:

This substudy is the Phase 2 portion of the study. In this part of the study, participants will receive either VZV modRNA vaccine at selected dose level/schedule/formulation or approved shingles vaccine. This selection was determined from data collected in Substudy A.

Participants will be involved in this study for up to 5 years.

A vizsgálat 14 csoportja

  • SubStudy A (SSA): Group 1A vizsgált kezelés

    Candidate 1, Dose Level 1, lyophilized, 0, 2 months schedule

    Kezelés: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection

  • SSA: Group 2A vizsgált kezelés

    Candidate 1, Dose Level 2, lyophilized, 0, 2 months schedule

    Kezelés: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection

  • SSA: Group 3A vizsgált kezelés

    Candidate 1, Dose Level 3, lyophilized, 0, 2 months schedule

    Kezelés: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection

  • SSA: Group 4A vizsgált kezelés

    Candidate 1, Dose Level 2, frozen, 0, 2 months schedule

    Kezelés: Candidate 1: PF-07915234: VZV modRNA Suspension for Injection

  • SSA: Group 5A vizsgált kezelés

    Candidate 1, Dose Level 2, Frozen, 0, 6 months schedule

    Kezelés: Candidate 1: PF-07915234: VZV modRNA Suspension for Injection

  • SSA: Group 6A vizsgált kezelés

    Candidate 2, frozen, 0, 2 months schedule

    Kezelés: Candidate 2: PF-07921188: VZV modRNA Suspension for Injection

  • SSA: Group 7A vizsgált kezelés

    Candidate 3, Frozen, 0, 2 months schedule

    Kezelés: Candidate 3: PF-07921186: VZV modRNA Suspension for Injection

  • SSA: Group 8Már használt kezelés, összehasonlításként

    Shingrix, 0, 2 months schedule

    Kezelés: Shingrix

  • SSA: Group 9Már használt kezelés, összehasonlításként

    Shingrix, 0, 6 months schedule

    Kezelés: Shingrix

  • SSA: Group 10A vizsgált kezelés

    Candidate 1, Dose level 4, lyophilized, 0, 6 months schedule (saline at month 6)

    Kezelés: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection

  • Substudy B (SSB): Group 1A vizsgált kezelés

    Candidate 2, Dose level 3, lyophilized, 0, 2 months schedule

    Kezelés: Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection

  • SSB: Group 2A vizsgált kezelés

    Candidate 2, Dose level 4, lyophilized, 0, 2 months schedule

    Kezelés: Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection

  • SSB: Group 3A vizsgált kezelés

    Candidate 2, Dose level 4, lyophilized, 0, 2 months schedule (saline at month 2)

    Kezelés: Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection

  • SSB: Group 4Már használt kezelés, összehasonlításként

    Shingrix, 0, 2 months schedule

    Kezelés: Shingrix

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A PHASE 1/2 RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS
A regiszteradat frissítve
2026. május 4.